PMID- 32835132
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221108
IS  - 2452-0144 (Print)
IS  - 2452-0144 (Electronic)
IS  - 2452-0144 (Linking)
VI  - 20
DP  - 2020 Sep
TI  - mTOR inhibition and p53 activation, microRNAs: The possible therapy against 
      pandemic COVID-19.
PG  - 100765
LID - 10.1016/j.genrep.2020.100765 [doi]
AB  - mTOR is a serine-threonine kinase and participates in cell proliferation, 
      cellular metabolism was found to be activated during Severe acute respiratory 
      syndrome coronavirus 2 (SARS-CoV-2) viral infection and replication. During viral 
      replication mTOR, downstream target genes such as ribosomal protein S6 kinase 
      beta 1 (S6K1) and Eukaryotic translational initiation factor 4E-binding protein1 
      (4-E-BP1) are activated result in ribosome biosynthesis and efficient protein 
      synthesis. In plasmacytoid dendritic cells (pDCs), mTOR plays a key role in the 
      association of adapter protein myeloid differentiation primary response gene 88 
      (MyD88), Toll-like receptor 9 (TLR9) and interferon regulatory factor (IRF-7) 
      leading to the transcriptional activation of type-I interferon (IFN) genes. 
      Viruses also inactivate the interferon alpha (IFN-alpha) pathway by impairing the IRF-7 
      mediated activation of IFN-alpha gene transcription. Thus, mammalian target of 
      rapamycin (mTOR) inhibitors can help in suppressing the early stages of viral 
      infection and replication. Interestingly, the key tumor-suppressor p53 protein 
      will undergo degradation by virus-encoded E3 ubiquitin ligase Ring-finger and CHY 
      zinc-finger domain-containing 1 (RCHY1) leading to an increased viral survival in 
      host cells. Thus, the mTOR inhibitors and p53 activators or microRNAs that 
      functions as p53 and can target 3'-UTR of mTOR and RPS6KB1 might effectively 
      inhibit viral replication in the human respiratory tract and lung cells.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ramaiah, Mekala Janaki
AU  - Ramaiah MJ
AD  - Functional Genomics and Disease Biology, School of Chemical and Biotechnology, 
      SASTRA Deemed University, Thanjavur 613401, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - United States
TA  - Gene Rep
JT  - Gene reports
JID - 101680713
EIN - Gene Rep. 2021 Sep;24:101054. PMID: 33615040
PMC - PMC7324924
OTO - NOTNLM
OT  - Dicer
OT  - MERS
OT  - MicroRNA
OT  - mTOR
OT  - nCOVID19 SARS-CoV
OT  - p53
COIS- The authors declare that he has no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
PMCR- 2020/06/30
CRDT- 2020/08/25 06:00
PHST- 2020/06/20 00:00 [received]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/06/30 00:00 [pmc-release]
AID - S2452-0144(20)30179-5 [pii]
AID - 100765 [pii]
AID - 10.1016/j.genrep.2020.100765 [doi]
PST - ppublish
SO  - Gene Rep. 2020 Sep;20:100765. doi: 10.1016/j.genrep.2020.100765. Epub 2020 Jun 
      30.